View Clinical Trial (Medical Research Study)

Effectiveness of Escitalopram in the Treatment of Body Dysmorphic Disorder - NCT00149799-02906(Clinical Trial 128142)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Providence
State:  
RI
Zip Code: 02906
Conditions: Anxiety Disorders - Somatoform Disorders
Purpose: This study will assess the relapse-prevention rate of escitalopram (Lexapro) in the treatment of body dysmorphic disorder.
Study summary: Body Dysmorphic Disorder (BDD) is a mental disorder in which a person is preoccupied by a very slight physical anomaly or an imagined defect in his or her appearance. It is associated with Obsessive Compulsive Disorder (OCD). Treatment of BDD usually reduces symptoms of the disorder, but some people's symptoms regress only for a short time and then reappear. Drugs that will reduce the risk of BDD-relapse are needed. Escitalopram, also known as Lexapro, is a serotonin reuptake inhibitor (SRI). It is an oral drug used to treat depression and general anxiety disorder. Its ability to prevent relapse of BDD has not yet been studied. This study will evaluate the relapse-prevention rate of escitalopram for the treatment of BDD. The study will start with an open-label phase, during which all participants will receive escitalopram for 14 weeks. Study visits will occur once weekly for the first month and once every other week for the remainder of the 14 weeks. At the end of this initial phase, those who show improvement will continue into a double-blind phase. The remaining participants will be randomly assigned to receive either escitalopram or placebo for an additional 6 months. Study visits will occur once every other week, with an additional visit at Week 15. Participants' improvement or return of BDD-related symptoms will be assessed. Throughout the 6 months, any participant showing relapse will be referred to alternate treatment.
Criteria: Inclusion Criteria: - Outpatient men and women age 18 and older - DSM-IV diagnosis of BDD within 6 months of study start date - Score of 24 or higher on the BDD-Yale-Brown Obsessive Compulsive Scale - Lives within driving distance of Boston, MA or Providence, RI Exclusion Criteria: - Suicidal or homicidal tendencies - Alcohol/drug abuse or dependence within 3 months of study entry
Study is available at: Rhode Island Hospital
Providence, RI 02906
United States

Primary Contact:
Martha Niemiec
Phone: 401-444-9884

Secondary Contact:
Ashley Shaw, BA
Email: bdd@partners.org
Phone: 1-617-643-4357
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 21, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.